Piper Sandler Reaffirms its Overweight Rating and $115 Price Target on Boston Scientific Corporation (BSX)

Boston Scientific Corporation (NYSE:BSX) is one of the 14 Stocks That Will Double in the Next 5 Years.

On September 25, 2025, Piper Sandler reaffirmed its Overweight rating and $115 price target on Boston Scientific Corporation (NYSE:BSX), a $145.3 billion medical products company, citing confidence in the CHAMPION-AF study as a major growth driver for its Watchman device. The study positions Boston Scientific’s Watchman as a potential first-line alternative to medication therapy, which could drive an annual revenue rise of 250 basis points later in the decade.

This follows recent turbulence caused by investor concerns around cardiology performance in Q3. Over the past 12 months, however, Boston Scientific has demonstrated excellent execution, as shown by its 21.4% sales increase.

Through its MedSurg and Cardiovascular segments, Boston Scientific Corporation (NYSE:BSX) develops, manufactures, and distributes medical devices for use across a wide range of interventional specialties worldwide. It is one of the Stocks That Will Double.

While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 14 Best IT Stocks to Buy for the Long Term.

Disclosure: None.